Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial.

Michael Fiegl, Brigitte Mlineritsch (Co-author), Michael Hubalek, Rupert Bartsch, Ursula Pluschnig, Günther G Steger

    Research output: Contribution to journalOriginal Articlepeer-review

    29 Citations (Web of Science)
    Original languageEnglish
    Pages (from-to)373
    JournalBMC CANCER
    Volume11
    DOIs
    Publication statusPublished - 2011

    Keywords

    • PHASE-II TRIAL
    • PALMAR-PLANTAR ERYTHRODYSESTHESIA
    • HAND-FOOT SYNDROME
    • 1ST-LINE TREATMENT
    • CHEMOTHERAPY
    • PHARMACOKINETICS
    • CARDIOTOXICITY
    • TRASTUZUMAB

    Cite this